Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer

Yang,Xiao‑Guang; Li,Yan‑Yu; Zhao,Dong‑Xue; Cui,Wei; Li,Han; Li,Xin‑Yu; Li,Yu‑Xin; Wang,Dun

doi:10.3892/or.2021.7950

Repurposing of a monoamine oxidase A inhibitor‑heptamethine carbocyanine dye conjugate for paclitaxel‑resistant non‑small cell lung cancer

Authors:
- Xiao‑Guang Yang
- Yan‑Yu Li
- Dong‑Xue Zhao
- Wei Cui
- Han Li
- Xin‑Yu Li
- Yu‑Xin Li
- Dun Wang
View Affiliations

Affiliations: School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China, Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, P.R. China
Published online on: January 22, 2021 https://doi.org/10.3892/or.2021.7950
Pages: 1306-1314

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) remains an intractable disease, which is primarily due to tumor metastasis and the acquisition of resistance to chemotherapy. Therefore, there is an urgent need for novel therapeutics to overcome these obstacles. It was recently demonstrated that upregulated expression of monoamine oxidase A (MAOA) contributes to the progression of NSCLC. G10, a tumor‑targeting representative conjugate of heptamethine carbocyanine dye and an inhibitor of MAOA, was shown to exert potent cytotoxic effects, comparable to those of doxorubicin, against prostate cancer cell lines, as well as moderate MAOA inhibitory activity. The research described herein aimed to extend our previous study on the antitumor function of G10 in NSCLC in vitro and in vivo, and to elucidate the mechanisms through which G10 exerts its antineoplastic effects. G10 markedly inhibited the proliferation of paclitaxel‑resistant NSCLC cells (H460/PTX) and reduced tumor cell migration and invasion. Gene expression profiling of paclitaxel‑resistant NSCLC cells following treatment with G10 demonstrated that the expression of genes associated with the extracellular matrix was significantly affected, particularly the metastasis‑related genes matrix metallopeptidase (MMP)2, MMP14 and COL6A, which exhibited notably reduced expression. Additionally, the results also demonstrated that MAOA‑related pathways, including AKT and hypoxia‑inducible factor‑1α, were also inhibited by G10 treatment and, subsequently, the downstream molecules of these pathways, such as p21, MMP2 and vascular endothelial growth factor, were also downregulated, highlighting a possible mechanism through which G10 suppresses tumor cell migration, invasion and proliferation. Importantly, in mouse NSCLC xenografts, combined treatment with G10 and paclitaxel resulted in pronounced inhibition of tumor growth. Taken together, the results of the present study highlight the potential of G10 as a novel therapeutic targeting MAOA in paclitaxel‑resistant NSCLC.

View Figures

View References

1	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
2	Chen Z, Fillmore CM, Hammerman PS, Kim CF and Wong KK: Non-small-cell lung cancers: A heterogeneous set of diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
3	Zhang C, Leighl NB, Wu YL and Zhong WZ: Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 12:452019. View Article : Google Scholar : PubMed/NCBI
4	Terlizzi M, Colarusso C, Pinto A and Sorrentino R: Drug resistance in non-small cell lung cancer (NSCLC): Impact of genetic and non-genetic alterations on therapeutic regimen and responsiveness. Pharmacol Ther. 202:140–148. 2019. View Article : Google Scholar : PubMed/NCBI
5	Shih JC, Chen K and Ridd MJ: Monoamine oxidase: From genes to behavior. Annu Rev Neurosci. 22:197–217. 1999. View Article : Google Scholar : PubMed/NCBI
6	Brunner HG, Nelen M, Breakefield XO, Ropers HH and Van Oost BA: Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. Science. 262:578–580. 1993. View Article : Google Scholar : PubMed/NCBI
7	Schwartz TL: A neuroscientific update on monoamine oxidase and its inhibitor. CNS Spectr. 18 (Suppl 1):S25–S33. 2013. View Article : Google Scholar
8	Lin YC, Chang YT, Campbell M, Lin TP, Pan CC, Lee HC, Shih JC and Chang PC: MAOA-a novel decision maker of apoptosis and autophagy in hormone refractory neuroendocrine prostate cancer cells. Sci Rep. 7:463382017. View Article : Google Scholar : PubMed/NCBI
9	Wu JB, Shao C, Li X, Li Q, Hu P, Shi C, Li Y, Chen YT, Yin F, Liao CP, et al: Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. J Clin Invest. 124:2891–2908. 2014. View Article : Google Scholar : PubMed/NCBI
10	Li PC, Siddiqi IN, Mottok A, Loo EY, Wu CH, Cozen W, Steidl C and Shih JC: Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma. J Pathol. 243:220–229. 2017. View Article : Google Scholar : PubMed/NCBI
11	Shih JC: Monoamine oxidase isoenzymes: Genes, functions and targets for behavior and cancer therapy. J Neural Transm (Vienna). 125:1553–1566. 2018. View Article : Google Scholar : PubMed/NCBI
12	Kushal S, Wang W, Vaikari VP, Kota R, Chen K, Yeh TS, Jhaveri N, Groshen SL, Olenyuk BZ, Chen TC, et al: Monoamine oxidase A (MAO A) inhibitors decrease glioma progression. Oncotarget. 7:13842–13853. 2016. View Article : Google Scholar : PubMed/NCBI
13	Wu JB, Lin TP, Gallagher JD, Kushal S, Chung LW, Zhau HE, Olenyuk BZ and Shih JC: Monoamine oxidase A inhibitor-near-infrared dye conjugate reduces prostate tumor growth. J Am Chem Soc. 137:2366–2374. 2015. View Article : Google Scholar : PubMed/NCBI
14	Liu F, Hu L, Ma Y, Huang B, Xiu Z, Zhang P, Zhou K and Tang X: Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer. Oncol Lett. 15:3245–3251. 2018.PubMed/NCBI
15	Yang X, Shao C, Wang R, Chu CY, Hu P, Master V, Osunkoya AO, Kim HL, Zhai HE and Chung LWK: Optical imaging of kidney cancer with novel near infrared heptamethine carbocyanine fluorescent dyes. J Urol. 189:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
16	Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, Zhu G, Cheng J, Yang VW, Cheng T, et al: Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res. 16:2833–2844. 2010. View Article : Google Scholar : PubMed/NCBI
17	Yi X, Yan F, Wang F, Qin W, Wu G, Yang X, Shao C, Chung LW and Yuan J: IR-780 dye for near-infrared fluorescence imaging in prostate cancer. Med Sci Monit. 21:511–517. 2015. View Article : Google Scholar : PubMed/NCBI
18	Wang Y, Liu T, Zhang E, Luo S, Tan X and Shi C: Preferential accumulation of the near infrared heptamethine dye IR-780 in the mitochondria of drug-resistant lung cancer cells. Biomaterials. 35:4116–4124. 2014. View Article : Google Scholar : PubMed/NCBI
19	Huang H, Long S, Li M, Gao F, Du J, Fan J and Peng X: Bromo-pentamethine as mitochondria-targeted photosensitizers for cancer cell apoptosis with high efficiency. Dyes Pigments. 149:633–638. 2018. View Article : Google Scholar
20	Shi C, Wu JB and Pan D: Review on near-infrared heptamethine cyanine dyes as theranostic agents for tumor imaging, targeting, and photodynamic therapy. J Biomed Opt. 21:509012016. View Article : Google Scholar : PubMed/NCBI
21	Zhang E, Luo S, Tan X and Shi C: Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent. Biomaterials. 35:771–778. 2014. View Article : Google Scholar : PubMed/NCBI
22	Usama SM, Lin CM and Burgess K: On the mechanisms of uptake of tumor-seeking cyanine dyes. Bioconjug Chem. 29:3886–3895. 2018. View Article : Google Scholar : PubMed/NCBI
23	Yang XG, Mou YH, Wang YJ, Wang J, Li YY, Kong RH, Ding M, Wang D and Guo C: Design, synthesis, and evaluation of monoamine oxidase A inhibitors-indocyanine dyes conjugates as targeted antitumor agents. Molecules. 24:14002019. View Article : Google Scholar
24	Wu JB, Chen K, Li Y, Lau YF and Shih JC: Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 23:4029–4038. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang L, Chen G, Lu X, Wang S, Han S, Li Y, Ping G, Jiang X, Li H, Yang J and Wu C: Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: Synthesis, anti-invasive and anti-angiogenic properties. Eur J Med Chem. 89:88–97. 2015. View Article : Google Scholar : PubMed/NCBI
26	Wang LH, Jiang XR, Yang JY, Bao XF, Chen JL, Liu X, Chen GL and Wu CF: SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 791:560–568. 2016. View Article : Google Scholar : PubMed/NCBI
27	Valastyan S and Weinberg RA: Tumor metastasis: Molecular insights and evolving paradigms. Cell. 147:275–292. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kai F, Drain AP and Weaver VM: The extracellular matrix modulates the metastatic journey. Dev Cell. 49:332–346. 2019. View Article : Google Scholar : PubMed/NCBI
29	Brown Y, Hua S and Tanwar PS: Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. Int J Biochem Cell Biol. 109:90–104. 2019. View Article : Google Scholar : PubMed/NCBI
30	Eble JA and Niland S: The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 36:171–198. 2019. View Article : Google Scholar : PubMed/NCBI
31	Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 43 (Suppl):S42–S51. 1999. View Article : Google Scholar : PubMed/NCBI
32	Chiu KH, Chang YH, Wu YS, Lee SH and Liao PC: Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J Proteome Res. 10:1110–1125. 2011. View Article : Google Scholar : PubMed/NCBI
33	Hou T, Tong C, Kazobinka G, Zhang W, Huang X, Huang Y and Zhang Y: Expression of COL6A1 predicts prognosis in cervical cancer patients. Am J Transl Res. 8:2838–2844. 2016.PubMed/NCBI
34	Theocharis AD, Skandalis SS, Gialeli C and Karamanos NK: Extracellular matrix structure. Adv Drug Deliv Rev. 97:4–27. 2016. View Article : Google Scholar : PubMed/NCBI
35	Semenza GL: Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 33:207–214. 2012. View Article : Google Scholar : PubMed/NCBI
36	Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, Ramos C, Garcia-Hernandez AA and Falfan-Valencia R: Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol. 137:57–83. 2019. View Article : Google Scholar : PubMed/NCBI
37	Hafner C, Landthaler M and Vogt T: Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations. Exp Dermatol. 19:e222–e227. 2010. View Article : Google Scholar : PubMed/NCBI
38	Nödling AR, Mills EM, Li X, Cardella D, Sayers EJ, Wu SH, Jones AT, Luk LYP and Tsai YH: Cyanine dye mediated mitochondrial targeting enhances the anti-cancer activity of small-molecule cargoes. Chem Commun (Camb). 56:4672–4675. 2020. View Article : Google Scholar : PubMed/NCBI
39	Choi PJ, Park TIH, Cooper E, Dragunow M, Denny WA and Jose J: Heptamethine cyanine dye mediated drug delivery: Hype or hope. Bioconjug Chem. 31:1724–1739. 2020. View Article : Google Scholar : PubMed/NCBI